A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Registration Number
- NCT05455320
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
- Detailed Description
Overall rationale of the study is that combination treatments of talquetamab, daratumumab, pomalidomide and dexamethasone may lead to enhanced clinical responses in treatment of relapsed or refractory multiple myeloma through multiple mechanisms of action. The study is divided into 3 phases: screening, treatment (until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first), and posttreatment follow-up (until death, withdrawal of consent, loss to follow-up, or end of the study, whichever occurs first). Efficacy, safety (physical examinations, neurologic examinations, Eastern Cooperative Oncology Group \[ECOG\] performance status, clinical laboratory tests, vital signs, and AE monitoring), pharmacokinetics (PK), immunogenicity, and biomarkers will be assessed at specified time points. Total duration of study will be up to 6 years 6 months.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 810
- Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurable disease at screening as defined by any of the following: i) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) (central laboratory); ii) Urine M-protein level >= 200 milligram (mg) per 24 hours (central laboratory); iii) Light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain >= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Relapsed or refractory disease as defined by: i) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria greater than (>) 60 days after cessation of treatment; ii) Refractory disease is defined as less than (<) 25 percent (%) reduction in monoclonal paraprotein (M-protein) or confirmed progressive disease by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Received at least 1 prior line of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide. Participants who have received only 1 prior line of antimyeloma therapy must be considered lenalidomide-refractory (that is, have demonstrated progressive disease by IMWG criteria on or within 60 days of completion of lenalidomide-containing regimen). Participants who have received >=2 prior lines of antimyeloma therapy must be considered lenalidomide exposed
- Documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
- Contraindications or life-threatening allergies, hypersensitivity, or intolerance to study drug excipients
- Disease is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody as defined per IMWG consensus guidelines (progression during treatment or within 60 days of completing therapy with an anti-CD38 monoclonal antibody)
- Received prior pomalidomide therapy
- A maximum cumulative dose of corticosteroids to >=140 milligrams (mg) of prednisone or equivalent within 14-day period before the first dose of study drug
- Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome), or primary amyloid light chain amyloidosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP) Talquetamab Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP) Daratumumab Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP) Pomalidomide Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP) Dexamethasone Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd) Daratumumab Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd) Pomalidomide Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd) Dexamethasone Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D) Talquetamab Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D) Daratumumab Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D) Dexamethasone Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) Up to 6 years 6 months PFS is defined as time from the date of randomization to the first documentation of disease progression, or death due to any cause, whichever is reported first.
- Secondary Outcome Measures
Name Time Method Overall Response (Partial Response [PR] or Better) Up to 6 years 6 months Overall response (PR or better) is defined as percentage of participants who have a PR or better per International Myeloma Working Group (IMWG) criteria.
Very Good Partial Response (VGPR) or Better Rate Up to 6 years 6 months VGPR or better rate is defined as the percentage of participants who achieve a VGPR or better according to IMWG response criteria.
Complete Response (CR) or Better Rate Up to 6 years 6 months CR or better rate is defined as the percentage of participants who achieve CR or better according to IMWG response criteria.
Overall Minimal Residual Disease (MRD) Negative CR Up to 6 years 6 months MRD-negative CR is defined as proportion of participants with CR or stringent CR who achieve MRD negativity at a threshold of 10\^-5 at any timepoint after the first dose of study drug and before disease progression or start of subsequent antimyeloma therapy.
Overall Survival (OS) Up to 6 years 6 months OS is defined as the time from the date of randomization to the date of the participant's death.
Progression-free Survival on Next-line Therapy (PFS2) Up to 6 years 6 months PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.
Time to Next Therapy (TTNT) Up to 6 years 6 months TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment.
Number of Participants with Adverse Events (AEs) Up to 6 years 6 months An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Number of Participants with AEs by Severity Up to 6 years 6 months Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE).
Serum Concentrations of Talquetamab Up to 6 years 6 months Serum concentrations of talquetamab will be reported.
Serum Concentrations of Daratumumab Up to 6 years 6 months Serum concentrations of daratumumab will be reported.
Number of Participants with Presence of Anti-Drug Antibodies (ADAs) to Talquetamab Up to 6 years 6 months Number of participants with presence ADAs to talquetamab will be reported.
Number of Participants With Presence of Anti-Drug Antibodies (ADAs) to Daratumumab Up to 6 years 6 months Number of participants with presence of ADAs to daratumumab will be reported.
Time to Worsening in Symptoms, Functioning, and Overall Health-Related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Up to 6 years 6 months The MySIm-Q is a disease-specific PRO assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30).
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c Up to 6 years 6 months The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed--length short form derived from the PROMIS Physical Function item bank.
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30 Up to 6 years 6 months Time to worsening in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported.
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE Up to 6 years 6 months The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability.
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L) Up to 6 years 6 months The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses.
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S) Up to 6 years 6 months The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population.
Change From Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Baseline up to 6 years 6 months The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30.
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c Baseline up to 6 years 6 months The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed-length short form derived from the PROMIS Physical Function item bank.
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30 Baseline up to 6 years 6 months Change from baseline in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported.
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE Baseline up to 6 years 6 months The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability.
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L) Baseline up to 6 years 6 months The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses.
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S) Baseline up to 6 years 6 months The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population.
Trial Locations
- Locations (216)
University of Kansas
🇺🇸Westwood, Kansas, United States
The Ohio State University Wexner Medical Center - James Cancer Hospital
🇺🇸Columbus, Ohio, United States
OhioHealth
🇺🇸Columbus, Ohio, United States
Massachusetts General
🇺🇸Boston, Massachusetts, United States
Houston Methodist Hospital
🇺🇸Houston, Texas, United States
University Of Minnesota
🇺🇸Minneapolis, Minnesota, United States
The First Hospital of Jilin University
🇨🇳Changchun, China
The second Xiangya Hospital of Central South University
🇨🇳ChangSha, China
Tongji Hospital of Tongji University
🇨🇳Shanghai, China
Tianjin cancer hospital
🇨🇳Tianjin, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
The University of Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
MedStar Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
University of Arkansas for Medical Sciences
🇺🇸Little Rock, Arkansas, United States
Norwalk Hospital-oncology
🇺🇸Norwalk, Connecticut, United States
University of Miami Health System
🇺🇸Miami, Florida, United States
Memorial Healthcare System
🇺🇸Hollywood, Florida, United States
University Of Illinois
🇺🇸Chicago, Illinois, United States
Levine Cancer Institute, Carolinas HealthCare System
🇺🇸Charlotte, North Carolina, United States
Johns Hopkins University
🇺🇸Baltimore, Maryland, United States
Boston University Medical Center
🇺🇸Boston, Massachusetts, United States
Baptist Cancer Center
🇺🇸Memphis, Tennessee, United States
Fred Hutchinson Cancer Research Center
🇺🇸Seattle, Washington, United States
Joe Arrington Cancer Research Treatment Center
🇺🇸Lubbock, Texas, United States
UZ Brussel
🇧🇪Brussel, Belgium
Sichuan Academy of Medical Science Sichuan Provincial People's Hospital
🇨🇳Chengdu, China
Fujian Medical University Union Hospital
🇨🇳Fuzhou, China
Sun Yat-Sen University Cancer Center
🇨🇳Guangzhou, China
Peking University Shenzhen Hospital
🇨🇳Shenzhen, China
First Affiliated Hospital SooChow University
🇨🇳Su Zhou, China
Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
🇨🇿Praha 2, Czechia
Hospital Sao Rafael
🇧🇷Salvador, Brazil
Liga Paranaense de Combate ao Cancer
🇧🇷Curitiba, Brazil
Centro de Pesquisa e Ensino em Oncologia de Santa Catarina - CEPEN
🇧🇷Florianopolis, Brazil
Fundacao Universidade de Caxias do Sul
🇧🇷Caxias do Sul, Brazil
CHC MontLegia
🇧🇪Liège, Belgium
UCL Mont Godinne
🇧🇪Yvoir, Belgium
Liga Norte Riograndense Contra O Cancer
🇧🇷Natal, Brazil
Beijing Chaoyang Hospital
🇨🇳Beijing, China
Nanjing Drum Tower Hospital
🇨🇳Nanjing, China
Peking University First Hospital
🇨🇳Beijing, China
Hospital Paulistano
🇧🇷Sao Paulo, Brazil
Guangdong Provincial People's Hospital
🇨🇳Guangzhou, China
A.O. Universitaria Ospedali Riuniti di Ancona
🇮🇹Ancona, Italy
ASST Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Peking Union Medical College Hospital
🇨🇳Beijing, China
Universitaetsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Japanese Red Cross Society Himeji Hospital
🇯🇵Hyogo, Japan
Universitaetsklinikum Leipzig
🇩🇪Leipzig, Germany
Fakultni Nemocnice Ostrava
🇨🇿Ostrava - Poruba, Czechia
Universitaetsklinikum Wuerzburg
🇩🇪Wuerzburg, Germany
The First Affiliated Hospital Zhejiang University College of Medicine
🇨🇳Hangzhou, China
Shanghai Fourth People s Hospital
🇨🇳Shanghai, China
Tongji Hospital, Tongji Medical College of HUST
🇨🇳Wuhan, China
APHP - Hopital Henri Mondor
🇫🇷Creteil, France
CHU de Nantes hotel Dieu
🇫🇷Nantes, France
CHU HOPITAL DE L'ARCHET - Hematology
🇫🇷Nice N/a, France
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
CHRU - Hôpital du Haut Lévêque - Centre François Magendie
🇫🇷Pessac, France
Alexandra General Hospital of Athens
🇬🇷Athens Attica, Greece
Anticancer Hospital of Thessaloniki Theageneio
🇬🇷Thessaloniki, Greece
Universitätsmedizin der Johannes Gutenberg Universität
🇩🇪Mainz, Germany
Asklepios Klinik Altona
🇩🇪Hamburg, Germany
CHU Hopital Saint Antoine
🇫🇷Paris Cedex 12, France
Hillel Yaffe Medical Center
🇮🇱Hadera, Israel
G Papanikolaou Hospital of Thessaloniki
🇬🇷Thessalonikis, Greece
Azienda Ospedaliera Spedali Civili di Brescia
🇮🇹Brescia, Italy
PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania
🇮🇹Catania, Italy
Ha'Emek Medical Center
🇮🇱Afula, Israel
Institut Universitaire du cancer de Toulouse-Oncopole
🇫🇷TOULOUSE Cedex 9, France
Gunma University Hospital
🇯🇵Gunma, Japan
Galilee Medical Center
🇮🇱Nahariya, Israel
Beilinson medical center
🇮🇱Petah Tikva, Israel
Shonan Kamakura General Hospital
🇯🇵Kamakura-shi, Japan
Rambam Medical Center
🇮🇱Haifa, Israel
Azienda Ospedaliera Policlinico S. Orsola-Malpighi
🇮🇹Bologna, Italy
Sourasky (Ichilov) Medical Center
🇮🇱Tel Aviv, Israel
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
Chiba Cancer Center
🇯🇵Chiba, Japan
Hyogo Medical University Hospital
🇯🇵Hyôgo, Japan
Hokkaido University Hospital
🇯🇵Sapporo-shi, Japan
Albert Schweitzer ziekenhuis-lokatie Dordwijk
🇳🇱Dordrecht, Netherlands
Arcispedale Santa Maria Nuova - IRCCS
🇮🇹Reggio Emilia, Italy
Dong-A University Hospital
🇰🇷Busan, Korea, Republic of
Chonnam National University Hwasun Hospital
🇰🇷Jeollanam-do, Korea, Republic of
IRCCS Ospedale Casa Sollievo della Sofferenza
🇮🇹San Giovanni Rotondo, Italy
Fukuoka University Hospital
🇯🇵Fukuoka, Japan
Tokyo Medical and Dental University Hospital
🇯🇵Bunkyo Ku, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Gachon University Gil Medical Center
🇰🇷Incheon, Korea, Republic of
Jeonbuk National University Hospital
🇰🇷Jeonju-si, Korea, Republic of
Iwate Medical University Hospital
🇯🇵Shiwa-gun, Japan
Maxima Medisch Centrum
🇳🇱Eindhoven, Netherlands
Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
🇵🇱Kielce, Poland
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp. Univ. Germans Trias I Pujol
🇪🇸Badalona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp Clinic de Barcelona
🇪🇸Barcelona, Spain
Ankara University Medical Faculty
🇹🇷Ankara, Turkey
Medipol Mega University Hospital
🇹🇷Istabul, Turkey
Hosp. Univ. Virgen de La Arrixaca
🇪🇸El Palmar, Murcia, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Ninewells Hospital & Medical School
🇬🇧Dundee, United Kingdom
Hosp Clinico Univ de Salamanca
🇪🇸Salamanca, Spain
Hosp. de Jerez de La Frontera
🇪🇸Jerez de la Frontera, Spain
Hosp. Univ. Dr. Peset
🇪🇸Valencia, Spain
Hosp Virgen de La Victoria
🇪🇸Malaga, Spain
Hosp. Univ. Ramon Y Cajal
🇪🇸Madrid, Spain
University Hospitals Plymouth NHS Trust
🇬🇧Plymouth, United Kingdom
Royal Marsden Hospital
🇬🇧Sutton, United Kingdom
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Hosp. de Leon
🇪🇸Leon, Spain
Blackpool Victoria Hospital
🇬🇧Blackpool, United Kingdom
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. de Canarias
🇪🇸San Cristóbal de La Laguna, Spain
Hosp. Univ. de La Princesa
🇪🇸Madrid, Spain
Dokuz Eylul University Medical Faculty
🇹🇷Izmir, Turkey
Nottingham City Hospital
🇬🇧Nottingham, United Kingdom
On Dokuz Mayis University Medical Faculty
🇹🇷Samsun, Turkey
Policlinico di Bari
🇮🇹Bari, Italy
Azienda Ospedaliera Universitaria di Padova
🇮🇹Padova, Italy
Presidio Ospedaliero Santo Spirito in Sassia
🇮🇹Roma, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
A.O.U. Città della Salute e della Scienza
🇮🇹Torino, Italy
Kansai Medical University Hospital
🇯🇵Hirakata, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Kyoto Kuramaguchi Medical Center
🇯🇵Kyoto, Japan
National Hospital Organization Matsumoto Medical Center
🇯🇵Matsumoto, Japan
Osaka University Hospital
🇯🇵Suita-shi, Japan
Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Hematology Unit
🇹🇷Ankara, Turkey
Liv Hospital Ankara
🇹🇷Ankara, Turkey
Antalya Training And Research Hospital
🇹🇷Antalya, Turkey
Newcastle Freeman Hospital
🇬🇧Newcastle Upon Tyne, United Kingdom
CHU de Montpellier - Hopital Saint-Eloi
🇫🇷Montpellier Cedex 5, France
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Sociedade Beneficente de Senhoras - Hospital Sírio Libanês
🇧🇷São Paulo, Brazil
Real e Benemerita Associacao Portuguesa de Beneficencia
🇧🇷São Paulo, Brazil
Clinica Sao Germano
🇧🇷São Paulo, Brazil
Hosp Univ Hm Sanchinarro
🇪🇸Madrid, Spain
Bnai Zion Medical Center
🇮🇱Haifa, Israel
Shaare Zedek Medical Center
🇮🇱Jerusalem, Israel
Carmel Medical Center
🇮🇱Haifa, Israel
Sheba Medical Center
🇮🇱Ramat Gan, Israel
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Fakultni nemocnice Olomouc
🇨🇿Olomouc, Czechia
University of Massachusetts Medical School
🇺🇸Worcester, Massachusetts, United States
Washington University School Of Medicine
🇺🇸Saint Louis, Missouri, United States
MD Anderson Cancer Center
🇺🇸Houston, Texas, United States
Huntsman Cancer Institute
🇺🇸Salt Lake City, Utah, United States
Clinique Saint Pierre
🇧🇪Ottignies, Belgium
Virga Jessa Ziekenhuis
🇧🇪Hasselt, Belgium
Hospitais Integradaos da Gavea S/A - DF Star
🇧🇷Brasilia, Brazil
Santa Casa de Misericordia de Belo Horizonte
🇧🇷Belo Horizonte, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷Sao Paulo, Brazil
Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
🇧🇷Rio de Janeiro, Brazil
Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science
🇨🇳Tianjin, China
Fakultni nemocnice Brno
🇨🇿Brno, Czechia
CHU Dijon
🇫🇷Dijon, France
Centre Leon Berard
🇫🇷Lyon, France
Fakultni nemocnice Kralovske Vinohrady
🇨🇿Praha 10, Czechia
Charite Campus Benjamin Franklin
🇩🇪Berlin, Germany
Universitaetsklinikum Koelnt
🇩🇪Koeln, Germany
Shamir Medical Center (Assaf Harofeh)
🇮🇱Be'er Ya'akov, Israel
Ziv Medical Center
🇮🇱Safed, Israel
Ospedale Villa Sofia-Cervello
🇮🇹Palermo, Italy
Ogaki Municipal Hospital
🇯🇵Gifu, Japan
Tohoku University Hospital
🇯🇵Sendai, Japan
Dokkyo Medical University Saitama Medical Center
🇯🇵Koshigaya, Japan
Hiroshima West Medical Center
🇯🇵Otake, Japan
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
🇵🇱Brzozow, Poland
Erasmus MC
🇳🇱Rotterdam, Netherlands
Pratia Onkologia Katowice
🇵🇱Katowice, Poland
Szpital Uniwersytecki w Krakowie
🇵🇱Krakow, Poland
Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
🇵🇱Torun, Poland
Hammersmith Hospital
🇬🇧London, United Kingdom
Kaohsiung Chang Gung Memorial Hospital
🇨🇳Kaohsiung, Taiwan
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
China Medical University Hospital
🇨🇳Taichung City, Taiwan
Istanbul University Istanbul Medical Faculty
🇹🇷Istanbul, Turkey
New Cross Hospital
🇬🇧Wolverhampton, United Kingdom
The Catholic University of Korea Seoul St Marys Hospital
🇰🇷Seoul, Korea, Republic of
University of Virginia
🇺🇸Charlottesville, Virginia, United States
University Hospitals Cleveland Medical Center
🇺🇸Cleveland, Ohio, United States
Szpital Kliniczny MSWiA z Warminsko Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii
🇵🇱Olsztyn, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
🇵🇱Szczecin, Poland
Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
🇵🇱Wroclaw, Poland
National Cancer Center
🇰🇷Gyeonggi-do, Korea, Republic of
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
Centrum Onkologii Ziemi Lubelskiej im. sw. Jana z Dukli
🇵🇱Lublin, Poland
UZA
🇧🇪Edegem, Belgium
University of Michigan Health System
🇺🇸Ann Arbor, Michigan, United States
University of North Carolina
🇺🇸Chapel Hill, North Carolina, United States
Novant Health
🇺🇸Winston-Salem, North Carolina, United States
Wake Forest Baptist Medical Center
🇺🇸Winston-Salem, North Carolina, United States
Tulane University Hospital & Clinics
🇺🇸New Orleans, Louisiana, United States
Ochsner Health System
🇺🇸New Orleans, Louisiana, United States
Virginia Commonwealth University - Massey Cancer Center
🇺🇸Richmond, Virginia, United States
SUNY Upstate Medical University
🇺🇸Syracuse, New York, United States
Rutgers Cancer Institute of New Jersey
🇺🇸New Brunswick, New Jersey, United States
Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP
🇧🇷Ribeirao Preto, Brazil
George Washington University
🇺🇸Washington, District of Columbia, United States
NYU Langone Health
🇺🇸New York, New York, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
Thomas Jefferson University
🇺🇸Philadelphia, Pennsylvania, United States
Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN
🇧🇷Florianopolis, Brazil
Fundacao Pio XII
🇧🇷Barretos, Brazil
Related News
Exploring GPRC5D as an Important Target for Multiple Myeloma - Cancer Network
- Prev
- 1
- Next